糖尿病患者血脂管理中国专家共识(2024版)

2024-04-24 中国循环杂志 发表于上海

本共识旨在传递重要临床进展,指导临床实践,以改善糖尿病患者的心血管结局。

中文标题:

糖尿病患者血脂管理中国专家共识(2024版)

发布机构:

发布日期:

2024-04-24

简要介绍:

糖尿病是动脉粥样硬化性心血管疾病(ASCVD)的重要独立危险因素,血脂异常在糖尿病患者的ASCVD发生和发展中起关键作用。目前我国糖尿病患者中血脂异常患病率高且控制现状不容乐观。因此,为了加强糖尿病患者的血脂管理,中国医师协会内分泌代谢科医师分会和国家心血管病专家委员会心血管代谢医学专业委员会组织专家,根据中国糖尿病患者的血脂管理现状,参考国内外新的循证证据和指南,制定了《糖尿病患者血脂管理中国专家共识(2024版)》。本共识内容涵盖糖尿病患者的血脂谱特点和血脂异常流行病学现状以及糖尿病全人群的ASCVD危险分层和血脂管理流程,首次将低密度脂蛋白胆固醇(LDL-C)与非高密度脂蛋白胆固醇(非HDL-C)均作为糖尿病患者血脂干预的首要靶点,并对糖尿病特殊人群(包括儿童和青少年、≥75岁老年人以及合并慢性肾脏病、代谢相关脂肪性肝病、妊娠的患者)的血脂管理策略进行了推荐。本共识旨在传递重要临床进展,指导临床实践,以改善糖尿病患者的心血管结局。

相关资料下载:
糖尿病患者血脂管理中国专家共识(2024版).pdf
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-11 田沛文 来自山西省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 坐井观天下 来自海南省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 ms5000000231838559 来自湖北省

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 慢川 来自浙江省

    学习了

    0

拓展阅读

小欧探案记|高甘油三酯与多病共存,血脂管理如何进行?

本例患者2型糖尿病、高血压、冠心病、高脂血症及痛风多病共存,给血脂管理带来了挑战。

小欧探案记|高甘油三酯血症致急性胰腺炎,血脂管理何为关键?

本病例展示了精准降脂策略在HTG性急性胰腺炎中的重要价值。

小欧探案记|糖尿病合并多重并发症患者TG飙升至59.93mmol/L!该如何破解血脂管理困局?

本案例验证了"血浆置换快速降TG+药物阶梯治疗"模式在极高危血脂异常患者中的有效性。

小欧探案记|青年男性顽固性高甘油三酯+反复胰腺炎,血脂管理如何破局?

本例患者顽固性高甘油三酯+反复胰腺炎,通过“贝特类+高纯度ω-3脂肪酸”双通道降脂策略,成功突破传统治疗瓶颈。

小欧探案记|ACS患者血脂管理:如何降低剩余风险?

针对本例患者血脂异常特征,临床团队实施了"双维度血脂优化管理方案",通过联用前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂与高纯度ω-3脂肪酸,协同调节低密度脂蛋白胆固醇和甘油三酯水平。

小欧探案记|传统降脂方案效果不佳+肝功异常,药物降脂路在何方?

本病例通过循证联合用药,成功实现血脂达标与肝损风险可控,为类似复杂病例提供了重要参考。

2015 ACC/AHA 二级预防血脂管理绩效评估指南

美国心脏病学会(ACC,American College of Cardiology) · 2015-12-10

2020 TES临床实践指南:内分泌疾病患者的血脂管理

美国内分泌学会(TES,The Endocrine Society) · 2020-12-01

2022 中国台湾指南:高风险患者的血脂管理—冠状动脉疾病、外周动脉疾病和缺血性卒中(更新版)

中国台湾血脂及动脉硬化学会(Taiwan Society of Lipids & Atherosclerosis) · 2022-04-08

2019年ESC/EAS血脂管理指南要点解读

中国医学科学院北京协和医学院国家心血管病中心阜外医院血脂异常与心血管疾病诊治中心 · 2019-11-20

2020 AACE临床实践指南:内分泌疾病患者的血脂管理

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2020-05-13